Literature DB >> 4372601

Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

G Miller, J Robinson, L Heston, M Lipman.   

Abstract

Biologic activities of extracellular Epstein-Barr virus (EB virus) from two laboratory strains, namely, P(3)J-HR-1 (P-H) from Burkitt lymphoma and B95-8 (B95) from infectious mononucleosis, were compared. Virus stocks from both sources contained approximately the same number of virions. Virus from the P-H line induced "early antigen" in six nonproducer EB virus genome carrier cell lines; virus from B95 did not induce "early antigen." Extracellular virus from B95 regularly caused lymphocytes from human umbilical cords to form continuous lines (immortalization); P-H virus did not cause primary cultures of human lymphocytes to grow continuously. B95 virus stimulated DNA synthesis as determined by rate of incorporation of [(3)H]thymidine into acid-insoluble material; P-H virus did not stimulate DNA synthesis. Pretreatment of lymphocytes with undiluted P-H virus inhibited immortalization and stimulation of DNA synthesis by B95 virus. The inhibitory properties of the P-H virus were sedimented at 100,000 x g and inactivated by heat and UV irradiation; interference by the P-H virus was neutralized by human serum with antibody to EB virus and not by antibody-negative human serum. The hypothesis most consistent with these results is that the P-H virus is defective in gene(s) needed for initiation of immortalization. We speculate that the absence of this gene allows early antigen to be expressed upon super-infection of nonproducer cell lines. The availability of two laboratory strains of EB virus which differ in biologic behavior provides starting material for analysis of the mechanism of lymphocyte immortalization by EB virus and of virus structural differences which affect immortalization.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4372601      PMCID: PMC434316          DOI: 10.1073/pnas.71.10.4006

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Appearance of Epstein-Barr virus-associated antigens in infected Raji cells.

Authors:  L Gergely; G Klein; I Ernberg
Journal:  Virology       Date:  1971-07       Impact factor: 3.616

2.  Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2.

Authors:  R Duff; F Rapp
Journal:  Nat New Biol       Date:  1971-09-08

3.  Induction of cellular DNA synthesis in human leukocytes by Epstein-Barr virus.

Authors:  P Gerber; B H Hoyer
Journal:  Nature       Date:  1971-05-07       Impact factor: 49.962

4.  Partial purification of the Epstein-Barr virus and some properties of its DNA.

Authors:  H Schulte-Holthausen; H zur Hausen
Journal:  Virology       Date:  1970-03       Impact factor: 3.616

5.  Identification of the filtrable leukocyte-transforming factor of QIMR-WIL cells as herpes-like virus.

Authors:  J H Pope; M K Horne; W Scott
Journal:  Int J Cancer       Date:  1969-05-15       Impact factor: 7.396

6.  Rapid semiquantitative method for screening large numbers of virus samples by negative staining electron microscopy.

Authors:  J H Monroe; P M Brandt
Journal:  Appl Microbiol       Date:  1970-08

7.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

8.  Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells.

Authors:  W Henle; V Diehl; G Kohn; H Zur Hausen; G Henle
Journal:  Science       Date:  1967-09-01       Impact factor: 47.728

9.  Transformation and chromosome changes induced by Epstein-Barr virus in normal human leukocyte cultures.

Authors:  P Gerper; J Whang-Peng; J H Monroe
Journal:  Proc Natl Acad Sci U S A       Date:  1969-07       Impact factor: 11.205

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more
  113 in total

1.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia.

Authors:  D M Walling; S N Edmiston; J W Sixbey; M Abdel-Hamid; L Resnick; N Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

3.  Characterization of the deletion and rearrangement in the BamHI C region of the X50-7 Epstein-Barr virus genome, a mutant viral strain which exhibits constitutive BamHI W promoter activity.

Authors:  C N Yandava; S H Speck
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Marked variation in the size of genomic plasmids among members of a family of related Epstein-Barr viruses.

Authors:  J L Kolman; C J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

5.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants.

Authors:  A Marchini; R Longnecker; E Kieff
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen.

Authors:  Natalie Sutkowski; Gang Chen; German Calderon; Brigitte T Huber
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Heterogeneity of Epstein-Barr virus. III. Comparison of a transforming and a nontransforming virus by partial denaturation mapping of their DNAs.

Authors:  H Delius; G W Bornkamm
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

9.  DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus.

Authors:  N Raab-Traub; R Pritchett; E Kieff
Journal:  J Virol       Date:  1978-08       Impact factor: 5.103

10.  Mapping of genes in BamHI fragment M of Epstein-Barr virus DNA that may determine the fate of viral infection.

Authors:  J Sample; G Lancz; M Nonoyama
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.